Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 21;16(2):72-74.
doi: 10.17925/HI.2022.16.2.72. eCollection 2022.

Can Percutaneous Coronary Intervention Revive a Failing Heart?

Saad M Ezad  1 , Matthew Ryan  1 , Divaka Perera  1
Affiliations

Can Percutaneous Coronary Intervention Revive a Failing Heart?

Saad M Ezad et al. Heart Int. .

Abstract

Coronary artery disease (CAD) remains the most common cause of heart failure with reduced ejection fraction; despite its prevalence, there is limited evidence to guide physicians in managing patients with CAD with percutaneous revascularization. The REVIVED-BCIS2 trial (ClinicalTrials.gov identifier: NCT01920048) represents the first randomized trial to assess the value of percutaneous coronary intervention in addition to optimal medical therapy in patients with ischaemic left ventricular systolic dysfunction and stable CAD. In this article, we review the results of the REVIVED-BCIS2 trial and compare them to the ClinicalTrials.gov Identifier: NCT00023595 trial (ClinicalTrials.gov Identifier: NCT00023595), which investigated the benefit of surgical revascularization on such patients. Finally, we suggest a pathway for physicians managing patients with ischaemic left ventricular systolic dysfunction based on the current evidence and highlight potential avenues for future research.

Keywords: Heart failure; ischaemic cardiomyopathy; left ventricular systolic dysfunction; percutaneous coronary intervention; percutaneous coronary revascularization; randomized clinical trial; viability.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Saad M Ezad is supported by a British Heart Foundation Clinical Research Training Fellowship (FS/CRTF/21/24118). Matthew Ryan and Divaka Perera have no financial or non-financial relationships or activities to declare in relation to this article.

Figures

Figure 1:
Figure 1:. Suggested management pathway for patients with ischaemic left ventricular systolic dysfunction
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Grüntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978;1:263. - PubMed
    1. Ryan M, Morgan H, Petrie MC, Perera D. Coronary revascularisation in patients with ischaemic cardiomyopathy. Heart. 2021;107:612–8. - PubMed
    1. Page BJ, Banas MD, Suzuki G. et al. Revascularization of chronic hibernating myocardium stimulates myocyte proliferation and partially reverses chronic adaptations to ischemia. J Am Coll Cardiol. 2015;65:684–97. - PMC - PubMed
    1. Patel MR, Calhoon JH, Dehmer GJ. et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for coronary revascularization in patients with stable ischemic heart disease: A report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2017;69:2212–41. - PubMed
    1. Neumann FJ, Sousa-Uva M, Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40:87–165. - PubMed

Associated data

LinkOut - more resources